Voyager Therapeutics, Inc. (VYGR) NASDAQ
$6.26 0.04 (0.56%)
Market Cap: $341.11M
As of 09/13/24 11:37 AM EDT. Market open.
Voyager Therapeutics, Inc. (VYGR)
NASDAQ
$6.26
0.04 (0.56%)
Market Cap: $341.11M
As of 09/13/24 11:37 AM EDT. Market open.
Add to Portfolio
Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's ... read more
COMPANY PROFILE
Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Alfred W. Sandrock Jr., M.D., Ph.D.
Full Time Employees
162
CEO Compensation (Base)
$624,000
CEO Compensation (Total)
$3.17M
Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Alfred W. Sandrock Jr., M.D., Ph.D.
Full Time Employees
162
CEO Compensation (Base)
$624,000
CEO Compensation (Total)
$3.17M
Address
75 Sidney Street, MA, Cambridge, 02139.
PRICE CHART FOR VOYAGER THERAPEUTICS, INC.
From:
To:
NEWS
INSIDEARBITRAGE ARTICLES
KEY STATS
Open
$6.26
Previous Close
$6.22
Days Range
$6.21 - $6.30
52 week range
$5.97 - $11.72
Volume
132,631
Avg. Volume (30 days)
431,635
Market Cap
$341.11M
Dividend Yield
-
P/E
23.17
Shares Outstanding
54,533,300
Open
$6.26
Previous Close
$6.22
Days Range
$6.21 - $6.30
52 week range
$5.97 - $11.72
Volume
132,631
Avg. Volume (30 days)
431,635
Market Cap
$341.11M
Dividend Yield
-
P/E
23.17
Shares Outstanding
54,533,300
FINANCIAL STATEMENTS FOR VOYAGER THERAPEUTICS, INC.
LOADING...
Open in: 
Open in:
INSIDER TRANSACTIONS FOR VOYAGER THERAPEUTICS, INC.
| Owner | Relationship | Date | Transaction | Cost | # Shares | Value($) | Total Shares | Form 4 |
| Swartz Robin | Chief Operating Officer | Apr 02, 2024 | Sale | $9.88 | 1,357 | 13,407 | 117,004 | Apr 03, 2024, 04:13 PM |
| Sandrock Alfred | President and CEO | Apr 02, 2024 | Sale | $9.86 | 12,115 | 119,454 | 322,839 | Apr 03, 2024, 04:10 PM |
| Swartz Robin | Chief Operating Officer | Feb 21, 2024 | Sale | $7.45 | 3,966 | 29,547 | 118,361 | Feb 22, 2024, 04:36 PM |
| Sandrock Alfred | President and CEO | Feb 21, 2024 | Sale | $7.46 | 13,033 | 97,226 | 334,954 | Feb 22, 2024, 04:34 PM |
| PFREUNDSCHUH PETER P. | Chief Financial Officer | Feb 21, 2024 | Sale | $7.46 | 3,764 | 28,079 | 175,669 | Feb 22, 2024, 04:32 PM |
| Carter Todd Alfred | Chief Scientific Officer | Feb 21, 2024 | Sale | $7.47 | 3,365 | 25,137 | 87,627 | Feb 22, 2024, 04:30 PM |
| Carter Todd Alfred | Chief Scientific Officer | Feb 20, 2024 | Sale | $7.68 | 602 | 4,623 | 90,992 | Feb 22, 2024, 04:30 PM |
| Swartz Robin | Chief Operating Officer | Jan 17, 2024 | Sale | $7.15 | 2,543 | 18,182 | 72,327 | Jan 19, 2024, 04:34 PM |
| Carter Todd Alfred | Chief Scientific Officer | Jan 17, 2024 | Sale | $7.18 | 1,266 | 9,090 | 53,094 | Jan 19, 2024, 04:32 PM |
| PFREUNDSCHUH PETER P. | Chief Financial Officer | Oct 03, 2023 | Sale | $6.99 | 13,567 | 94,833 | 149,433 | Oct 05, 2023, 04:41 PM |
| Carter Todd Alfred | Chief Scientific Officer | Sep 15, 2023 | Option Exercise | $2.85 | 5,000 | 14,250 | 64,860 | Sep 18, 2023, 04:44 PM |
| Carter Todd Alfred | Chief Scientific Officer | Sep 15, 2023 | Sale | $8.16 | 10,500 | 85,680 | 54,360 | Sep 18, 2023, 04:44 PM |
| Carter Todd Alfred | Chief Scientific Officer | Jul 06, 2023 | Sale | $10.80 | 5,500 | 59,400 | 59,860 | Jul 10, 2023, 04:42 PM |
| Carter Todd Alfred | Chief Scientific Officer | Jun 30, 2023 | Option Exercise | $2.85 | 5,000 | 14,250 | 70,360 | Jul 05, 2023, 04:32 PM |
| Carter Todd Alfred | Chief Scientific Officer | Jun 30, 2023 | Sale | $11.41 | 5,000 | 57,050 | 65,360 | Jul 05, 2023, 04:32 PM |
| Sandrock Alfred | President and CEO | Apr 03, 2023 | Sale | $7.83 | 7,437 | 58,232 | 214,618 | Apr 05, 2023, 05:04 PM |
| Swartz Robin | Chief Operating Officer | Apr 03, 2023 | Sale | $7.83 | 1,259 | 9,858 | 71,617 | Apr 05, 2023, 05:02 PM |
| Carter Todd Alfred | Chief Scientific Officer | Mar 20, 2023 | Sale | $7.76 | 2,193 | 17,018 | 65,360 | Mar 22, 2023, 04:49 PM |
| Swartz Robin | Chief Operating Officer | Mar 20, 2023 | Sale | $7.76 | 3,654 | 28,355 | 72,876 | Mar 22, 2023, 04:48 PM |
| Hesslein Robert W. | Senior VP & General Counsel | Mar 20, 2023 | Sale | $7.76 | 4,410 | 34,222 | 102,200 | Mar 22, 2023, 04:47 PM |
| Swartz Robin | Chief Operating Officer | Mar 15, 2023 | Sale | $8.20 | 15,373 | 126,059 | 76,530 | Mar 17, 2023, 04:37 PM |
| NEUROCRINE BIOSCIENCES INC | 10% Owner | Feb 23, 2023 | Buy | $8.88 | 4,395,588 | 39,032,822 | 8,575,316 | Feb 24, 2023, 06:15 AM |
| Hesslein Robert W. | Senior VP & General Counsel | Feb 17, 2023 | Sale | $7.45 | 3,297 | 24,563 | 106,610 | Feb 22, 2023, 08:58 PM |
| Carter Todd Alfred | Chief Scientific Officer | Feb 17, 2023 | Sale | $7.45 | 738 | 5,498 | 67,553 | Feb 22, 2023, 08:57 PM |
| Carter Todd Alfred | Chief Scientific Officer | Feb 13, 2023 | Sale | $7.67 | 797 | 6,113 | 34,291 | Feb 15, 2023, 04:53 PM |
| Hesslein Robert W. | Senior VP & General Counsel | Feb 13, 2023 | Sale | $7.67 | 2,868 | 21,998 | 109,907 | Feb 15, 2023, 04:52 PM |
| Third Rock Ventures III, L.P. | 10% Owner | Feb 01, 2023 | Sale | $9.32 | 128,642 | 1,198,943 | 4,685,291 | Feb 01, 2023, 07:26 PM |
| Third Rock Ventures III, L.P. | 10% Owner | Jan 31, 2023 | Sale | $9.25 | 185,000 | 1,711,250 | 4,813,933 | Feb 01, 2023, 07:26 PM |
| Third Rock Ventures III, L.P. | 10% Owner | Jan 30, 2023 | Sale | $9.03 | 75,000 | 677,250 | 4,998,933 | Feb 01, 2023, 07:26 PM |
| Third Rock Ventures III, L.P. | 10% Owner | Jan 27, 2023 | Sale | $9.02 | 50,000 | 451,000 | 5,073,933 | Jan 31, 2023, 04:30 PM |
| Third Rock Ventures III, L.P. | 10% Owner | Jan 25, 2023 | Sale | $9.22 | 50,000 | 461,000 | 5,123,933 | Jan 26, 2023, 05:23 PM |
| Third Rock Ventures III, L.P. | 10% Owner | Jan 24, 2023 | Sale | $9.27 | 100,000 | 927,000 | 5,173,933 | Jan 26, 2023, 05:23 PM |
| Third Rock Ventures III, L.P. | 10% Owner | Jan 23, 2023 | Sale | $9.06 | 55,000 | 498,300 | 5,273,933 | Jan 24, 2023, 06:20 PM |
| Third Rock Ventures III, L.P. | 10% Owner | Jan 20, 2023 | Sale | $9.15 | 100,000 | 915,000 | 5,328,933 | Jan 24, 2023, 06:20 PM |
| Hesslein Robert W. | Senior VP & General Counsel | Jan 17, 2023 | Sale | $9.85 | 2,188 | 21,549 | 113,567 | Jan 19, 2023, 04:57 PM |
| Carter Todd Alfred | Chief Scientific Officer | Jan 17, 2023 | Sale | $9.85 | 1,106 | 10,892 | 35,488 | Jan 19, 2023, 04:55 PM |
| Swartz Robin | Chief Operating Officer | Jan 17, 2023 | Sale | $9.85 | 2,188 | 21,549 | 52,695 | Jan 19, 2023, 04:53 PM |
| EcoR1 Capital, LLC | 10% Owner | Jan 11, 2023 | Sale | $8.50 | 110,000 | 934,615 | 3,851,507 | Jan 11, 2023, 06:26 PM |
| EcoR1 Capital, LLC | 10% Owner | Jan 10, 2023 | Sale | $8.05 | 336,400 | 2,709,433 | 3,961,507 | Jan 11, 2023, 06:26 PM |
| EcoR1 Capital, LLC | 10% Owner | Jan 09, 2023 | Sale | $7.67 | 456,000 | 3,498,295 | 4,297,907 | Jan 11, 2023, 06:26 PM |
| Carter Todd Alfred | Chief Scientific Officer | Dec 31, 2022 | Option Exercise | $5.17 | 388 | 2,006 | 36,582 | Jan 10, 2023, 04:07 PM |
| Carter Todd Alfred | Chief Scientific Officer | Jan 06, 2023 | Sale | $6.41 | 388 | 2,487 | 36,194 | Jan 10, 2023, 04:07 PM |
| Third Rock Ventures III, L.P. | 10% Owner | Aug 24, 2022 | Sale | $6.09 | 149,972 | 913,330 | 5,628,933 | Aug 26, 2022, 04:15 PM |
| Third Rock Ventures III, L.P. | 10% Owner | Aug 25, 2022 | Sale | $6.22 | 200,000 | 1,244,000 | 5,428,933 | Aug 26, 2022, 04:15 PM |
| Third Rock Ventures III, L.P. | 10% Owner | Aug 16, 2022 | Sale | $6.04 | 128,456 | 775,874 | 5,778,905 | Aug 18, 2022, 04:15 PM |
| Third Rock Ventures III, L.P. | 10% Owner | Aug 15, 2022 | Sale | $6.04 | 135,808 | 820,280 | 5,907,361 | Aug 16, 2022, 04:22 PM |
| Third Rock Ventures III, L.P. | 10% Owner | Aug 12, 2022 | Sale | $6.12 | 348,007 | 2,129,803 | 6,043,169 | Aug 16, 2022, 04:22 PM |
| PIERCE GLENN | Director | Jul 14, 2022 | Sale | $6.70 | 9,512 | 63,730 | 16,788 | Jul 18, 2022, 05:34 PM |
| Higgins Michael J | Director | Jul 14, 2022 | Sale | $6.70 | 13,891 | 93,070 | 31,314 | Jul 18, 2022, 05:32 PM |
| EcoR1 Capital, LLC | 10% Owner | Jun 23, 2022 | Buy | $5.66 | 376,000 | 2,126,543 | 4,753,907 | Jun 23, 2022, 05:21 PM |
| EcoR1 Capital, LLC | 10% Owner | Jun 21, 2022 | Buy | $5.28 | 101,400 | 535,504 | 4,377,907 | Jun 23, 2022, 05:21 PM |
| Swartz Robin | Chief Operating Officer | Apr 04, 2022 | Sale | $8.25 | 1,527 | 12,598 | 52,060 | Apr 06, 2022, 04:34 PM |
| Hesslein Robert W. | Senior VP & General Counsel | Apr 04, 2022 | Sale | $8.25 | 2,786 | 22,985 | 114,963 | Apr 06, 2022, 04:34 PM |
| Swartz Robin | Chief Operating Officer | Mar 21, 2022 | Sale | $8.29 | 4,413 | 36,604 | 53,638 | Mar 23, 2022, 06:40 PM |
| Hesslein Robert W. | Senior VP & General Counsel | Mar 21, 2022 | Sale | $8.29 | 4,955 | 41,100 | 117,807 | Mar 23, 2022, 06:39 PM |
| Burek Julie | VP, Finance | Mar 21, 2022 | Sale | $8.29 | 2,649 | 21,972 | 52,489 | Mar 23, 2022, 06:36 PM |
| Hesslein Robert W. | Senior VP & General Counsel | Feb 17, 2022 | Sale | $3.55 | 4,100 | 14,555 | 122,704 | Feb 22, 2022, 04:37 PM |
| Burek Julie | VP, Finance | Feb 17, 2022 | Sale | $3.55 | 789 | 2,801 | 55,107 | Feb 22, 2022, 04:35 PM |
| Hesslein Robert W. | Senior VP & General Counsel | Feb 11, 2022 | Sale | $3.36 | 3,252 | 10,927 | 126,804 | Feb 15, 2022, 04:42 PM |
| Burek Julie | VP, Finance | Feb 11, 2022 | Sale | $3.36 | 361 | 1,213 | 55,896 | Feb 15, 2022, 04:40 PM |
| Burek Julie | VP, Finance | Dec 31, 2021 | Option Exercise | $2.30 | 3,063 | 7,045 | 49,585 | Jan 14, 2022, 06:14 PM |
| Burek Julie | VP, Finance | Jan 12, 2022 | Sale | $3.06 | 265 | 811 | 46,257 | Jan 14, 2022, 06:14 PM |
| Burek Julie | VP, Finance | Jan 03, 2022 | Sale | $2.83 | 3,063 | 8,668 | 46,522 | Jan 14, 2022, 06:14 PM |
| Khwaja Omar | See remarks | May 21, 2021 | Sale | $4.03 | 3,516 | 14,169 | 120,509 | May 25, 2021, 04:31 PM |
| Hesslein Robert W. | Senior VP & General Counsel | Apr 05, 2021 | Sale | $4.95 | 3,292 | 16,295 | 110,056 | Apr 07, 2021, 05:44 PM |
| Dorval Allison | Chief Financial Officer | Feb 11, 2021 | Sale | $7.55 | 3,186 | 24,054 | 45,894 | Feb 16, 2021, 04:10 PM |
| Hesslein Robert W. | Senior VP & General Counsel | Feb 11, 2021 | Sale | $7.55 | 3,186 | 24,054 | 49,348 | Feb 16, 2021, 04:08 PM |
| Khwaja Omar | See remarks | Feb 11, 2021 | Sale | $7.55 | 3,475 | 26,236 | 53,025 | Feb 16, 2021, 04:06 PM |
| Turenne Andre | President & CEO | Feb 11, 2021 | Sale | $7.55 | 7,977 | 60,226 | 148,375 | Feb 16, 2021, 12:00 AM |
| Turenne Andre | President & CEO | Jan 12, 2021 | Sale | $8.62 | 10,443 | 90,019 | 156,352 | Jan 14, 2021, 05:59 PM |
| Dorval Allison | Chief Financial Officer | Jan 12, 2021 | Sale | $8.62 | 2,942 | 25,360 | 49,080 | Jan 14, 2021, 05:57 PM |
| Khwaja Omar | See remarks | May 21, 2020 | Sale | $12.96 | 3,500 | 45,360 | 56,500 | May 22, 2020, 06:15 PM |
| Hesslein Robert W. | Senior VP & General Counsel | Apr 03, 2020 | Sale | $8.51 | 3,091 | 26,304 | 52,534 | Apr 07, 2020, 05:24 PM |
| Dorval Allison | Chief Financial Officer | Jan 21, 2020 | Sale | $13.36 | 3,128 | 41,790 | 24,522 | Jan 29, 2020, 05:27 PM |
| Ottmer Matthew P. | Chief Operating Officer | Jan 21, 2020 | Sale | $13.36 | 3,724 | 49,753 | 26,276 | Jan 29, 2020, 05:26 PM |
| Turenne Andre | President & CEO | Jan 21, 2020 | Sale | $13.36 | 10,705 | 143,019 | 85,545 | Jan 29, 2020, 05:26 PM |
| NEUROCRINE BIOSCIENCES INC | 10% Owner | Mar 12, 2019 | Buy | $11.96 | 4,179,728 | 49,999,995 | 4,179,728 | Mar 14, 2019, 04:34 PM |
| GERAGHTY JAMES A | Director | Sep 10, 2018 | Buy | $19.39 | 3,000 | 58,170 | 76,588 | Sep 12, 2018, 12:00 AM |
| PIERCE GLENN | Director | Sep 12, 2018 | Buy | $18.44 | 5,000 | 92,200 | 5,000 | Sep 12, 2018, 12:00 AM |
| GERAGHTY JAMES A | Director | Aug 17, 2018 | Buy | $18.31 | 3,000 | 54,930 | 73,588 | Aug 21, 2018, 04:05 PM |
| Ravina Bernard | Chief Medical Officer | Apr 10, 2018 | Sale | $18.38 | 2,451 | 45,049 | 0 | Apr 12, 2018, 04:01 PM |
| Henderson Jane | Sr. V.P. & CFO, Corp. Dev. | Mar 23, 2018 | Option Exercise | $11.97 | 11,200 | 134,064 | 11,200 | Mar 26, 2018, 04:02 PM |
| Henderson Jane | Sr. V.P. & CFO, Corp. Dev. | Mar 22, 2018 | Option Exercise | $11.97 | 19,900 | 238,203 | 19,900 | Mar 26, 2018, 04:02 PM |
| Henderson Jane | Sr. V.P. & CFO, Corp. Dev. | Mar 23, 2018 | Sale | $20.52 | 11,200 | 229,824 | 0 | Mar 26, 2018, 04:02 PM |
| Henderson Jane | Sr. V.P. & CFO, Corp. Dev. | Mar 22, 2018 | Sale | $21.07 | 19,900 | 419,293 | 0 | Mar 26, 2018, 04:02 PM |
| Henderson Jane | CFO & SVP, Corp. Dev. | Mar 16, 2018 | Option Exercise | $11.97 | 15,416 | 184,530 | 15,416 | Mar 20, 2018, 05:43 PM |
| Henderson Jane | CFO & SVP, Corp. Dev. | Mar 19, 2018 | Option Exercise | $11.97 | 1,900 | 22,743 | 1,900 | Mar 20, 2018, 05:43 PM |
| Henderson Jane | CFO & SVP, Corp. Dev. | Mar 19, 2018 | Sale | $21.76 | 1,900 | 41,344 | 0 | Mar 20, 2018, 05:43 PM |
| Henderson Jane | CFO & SVP, Corp. Dev. | Mar 16, 2018 | Sale | $22.15 | 15,416 | 341,464 | 0 | Mar 20, 2018, 05:43 PM |
| Ravina Bernard | Chief Medical Officer | Mar 12, 2018 | Sale | $25.16 | 2,451 | 61,667 | 2,451 | Mar 14, 2018, 04:07 PM |
| Sah Dinah Ph.D. | Chief Scientific Officer | Feb 27, 2018 | Option Exercise | $9.98 | 15,623 | 155,845 | 154,311 | Mar 01, 2018, 06:00 PM |
| Sah Dinah Ph.D. | Chief Scientific Officer | Feb 27, 2018 | Sale | $30.00 | 15,623 | 468,690 | 138,688 | Mar 01, 2018, 06:00 PM |
| Ravina Bernard | Chief Medical Officer | Feb 12, 2018 | Sale | $18.24 | 2,451 | 44,706 | 4,902 | Feb 13, 2018, 04:10 PM |
| Ravina Bernard | Chief Medical Officer | Jan 10, 2018 | Sale | $16.40 | 3,630 | 59,532 | 7,353 | Jan 12, 2018, 08:57 AM |
| Ravina Bernard | Chief Medical Officer | Dec 11, 2017 | Sale | $13.63 | 5,490 | 74,829 | 10,983 | Dec 13, 2017, 04:02 PM |
| Ravina Bernard | Chief Medical Officer | Nov 10, 2017 | Sale | $13.26 | 5,490 | 72,797 | 16,473 | Nov 13, 2017, 04:15 PM |
| Ravina Bernard | Chief Medical Officer | Oct 10, 2017 | Sale | $20.33 | 10,980 | 223,223 | 21,963 | Oct 12, 2017, 07:28 PM |
| Ravina Bernard | Chief Medical Officer | Sep 11, 2017 | Sale | $14.30 | 10,980 | 157,014 | 32,943 | Sep 13, 2017, 05:23 PM |
| Ravina Bernard | Chief Medical Officer | Jul 20, 2017 | Sale | $10.00 | 5,490 | 54,900 | 49,413 | Sep 13, 2017, 05:23 PM |
| Ravina Bernard | Chief Medical Officer | Sep 05, 2017 | Sale | $10.00 | 5,490 | 54,900 | 17,157 | Sep 06, 2017, 04:38 PM |
| PAUL STEVEN M | President and CEO | Jan 14, 2016 | Buy | $14.07 | 10,000 | 140,690 | 872,351 | Jan 15, 2016, 05:01 PM |
| Sanofi | Former 10% owner | Nov 16, 2015 | Buy | $14.00 | 125,000 | 1,750,000 | 2,477,941 | Nov 18, 2015, 02:26 PM |
Load More Insider Transactions
Buy
Sale
Option Exercise
| Owner | Relationship | Date | Value($) |
| Swartz Robin | Chief Operating Officer | 04/02/2024 | 13,407 |
| Sandrock Alfred | President and CEO | 04/02/2024 | 119,454 |
| Swartz Robin | Chief Operating Officer | 02/21/2024 | 29,547 |
| Sandrock Alfred | President and CEO | 02/21/2024 | 97,226 |
| PFREUNDSCHUH PETER P. | Chief Financial Officer | 02/21/2024 | 28,079 |
| Carter Todd Alfred | Chief Scientific Officer | 02/21/2024 | 25,137 |
| Carter Todd Alfred | Chief Scientific Officer | 02/20/2024 | 4,623 |
| Swartz Robin | Chief Operating Officer | 01/17/2024 | 18,182 |
| Carter Todd Alfred | Chief Scientific Officer | 01/17/2024 | 9,090 |
| PFREUNDSCHUH PETER P. | Chief Financial Officer | 10/03/2023 | 94,833 |
| Carter Todd Alfred | Chief Scientific Officer | 09/15/2023 | 14,250 |
| Carter Todd Alfred | Chief Scientific Officer | 09/15/2023 | 85,680 |
| Carter Todd Alfred | Chief Scientific Officer | 07/06/2023 | 59,400 |
| Carter Todd Alfred | Chief Scientific Officer | 06/30/2023 | 14,250 |
| Carter Todd Alfred | Chief Scientific Officer | 06/30/2023 | 57,050 |
| Sandrock Alfred | President and CEO | 04/03/2023 | 58,232 |
| Swartz Robin | Chief Operating Officer | 04/03/2023 | 9,858 |
| Carter Todd Alfred | Chief Scientific Officer | 03/20/2023 | 17,018 |
| Swartz Robin | Chief Operating Officer | 03/20/2023 | 28,355 |
| Hesslein Robert W. | Senior VP & General Counsel | 03/20/2023 | 34,222 |
| Swartz Robin | Chief Operating Officer | 03/15/2023 | 126,059 |
| NEUROCRINE BIOSCIENCES INC | 10% Owner | 02/23/2023 | 39,032,822 |
| Hesslein Robert W. | Senior VP & General Counsel | 02/17/2023 | 24,563 |
| Carter Todd Alfred | Chief Scientific Officer | 02/17/2023 | 5,498 |
| Carter Todd Alfred | Chief Scientific Officer | 02/13/2023 | 6,113 |
| Hesslein Robert W. | Senior VP & General Counsel | 02/13/2023 | 21,998 |
| Third Rock Ventures III, L.P. | 10% Owner | 02/01/2023 | 1,198,943 |
| Third Rock Ventures III, L.P. | 10% Owner | 01/31/2023 | 1,711,250 |
| Third Rock Ventures III, L.P. | 10% Owner | 01/30/2023 | 677,250 |
| Third Rock Ventures III, L.P. | 10% Owner | 01/27/2023 | 451,000 |
| Third Rock Ventures III, L.P. | 10% Owner | 01/25/2023 | 461,000 |
| Third Rock Ventures III, L.P. | 10% Owner | 01/24/2023 | 927,000 |
| Third Rock Ventures III, L.P. | 10% Owner | 01/23/2023 | 498,300 |
| Third Rock Ventures III, L.P. | 10% Owner | 01/20/2023 | 915,000 |
| Hesslein Robert W. | Senior VP & General Counsel | 01/17/2023 | 21,549 |
| Carter Todd Alfred | Chief Scientific Officer | 01/17/2023 | 10,892 |
| Swartz Robin | Chief Operating Officer | 01/17/2023 | 21,549 |
| EcoR1 Capital, LLC | 10% Owner | 01/11/2023 | 934,615 |
| EcoR1 Capital, LLC | 10% Owner | 01/10/2023 | 2,709,433 |
| EcoR1 Capital, LLC | 10% Owner | 01/09/2023 | 3,498,295 |
| Carter Todd Alfred | Chief Scientific Officer | 12/31/2022 | 2,006 |
| Carter Todd Alfred | Chief Scientific Officer | 01/06/2023 | 2,487 |
| Third Rock Ventures III, L.P. | 10% Owner | 08/24/2022 | 913,330 |
| Third Rock Ventures III, L.P. | 10% Owner | 08/25/2022 | 1,244,000 |
| Third Rock Ventures III, L.P. | 10% Owner | 08/16/2022 | 775,874 |
| Third Rock Ventures III, L.P. | 10% Owner | 08/15/2022 | 820,280 |
| Third Rock Ventures III, L.P. | 10% Owner | 08/12/2022 | 2,129,803 |
| PIERCE GLENN | Director | 07/14/2022 | 63,730 |
| Higgins Michael J | Director | 07/14/2022 | 93,070 |
| EcoR1 Capital, LLC | 10% Owner | 06/23/2022 | 2,126,543 |
| EcoR1 Capital, LLC | 10% Owner | 06/21/2022 | 535,504 |
| Swartz Robin | Chief Operating Officer | 04/04/2022 | 12,598 |
| Hesslein Robert W. | Senior VP & General Counsel | 04/04/2022 | 22,985 |
| Swartz Robin | Chief Operating Officer | 03/21/2022 | 36,604 |
| Hesslein Robert W. | Senior VP & General Counsel | 03/21/2022 | 41,100 |
| Burek Julie | VP, Finance | 03/21/2022 | 21,972 |
| Hesslein Robert W. | Senior VP & General Counsel | 02/17/2022 | 14,555 |
| Burek Julie | VP, Finance | 02/17/2022 | 2,801 |
| Hesslein Robert W. | Senior VP & General Counsel | 02/11/2022 | 10,927 |
| Burek Julie | VP, Finance | 02/11/2022 | 1,213 |
| Burek Julie | VP, Finance | 12/31/2021 | 7,045 |
| Burek Julie | VP, Finance | 01/12/2022 | 811 |
| Burek Julie | VP, Finance | 01/03/2022 | 8,668 |
| Khwaja Omar | See remarks | 05/21/2021 | 14,169 |
| Hesslein Robert W. | Senior VP & General Counsel | 04/05/2021 | 16,295 |
| Dorval Allison | Chief Financial Officer | 02/11/2021 | 24,054 |
| Hesslein Robert W. | Senior VP & General Counsel | 02/11/2021 | 24,054 |
| Khwaja Omar | See remarks | 02/11/2021 | 26,236 |
| Turenne Andre | President & CEO | 02/11/2021 | 60,226 |
| Turenne Andre | President & CEO | 01/12/2021 | 90,019 |
| Dorval Allison | Chief Financial Officer | 01/12/2021 | 25,360 |
| Khwaja Omar | See remarks | 05/21/2020 | 45,360 |
| Hesslein Robert W. | Senior VP & General Counsel | 04/03/2020 | 26,304 |
| Dorval Allison | Chief Financial Officer | 01/21/2020 | 41,790 |
| Ottmer Matthew P. | Chief Operating Officer | 01/21/2020 | 49,753 |
| Turenne Andre | President & CEO | 01/21/2020 | 143,019 |
| NEUROCRINE BIOSCIENCES INC | 10% Owner | 03/12/2019 | 49,999,995 |
| GERAGHTY JAMES A | Director | 09/10/2018 | 58,170 |
| PIERCE GLENN | Director | 09/12/2018 | 92,200 |
| GERAGHTY JAMES A | Director | 08/17/2018 | 54,930 |
| Ravina Bernard | Chief Medical Officer | 04/10/2018 | 45,049 |
| Henderson Jane | Sr. V.P. & CFO, Corp. Dev. | 03/23/2018 | 134,064 |
| Henderson Jane | Sr. V.P. & CFO, Corp. Dev. | 03/22/2018 | 238,203 |
| Henderson Jane | Sr. V.P. & CFO, Corp. Dev. | 03/23/2018 | 229,824 |
| Henderson Jane | Sr. V.P. & CFO, Corp. Dev. | 03/22/2018 | 419,293 |
| Henderson Jane | CFO & SVP, Corp. Dev. | 03/16/2018 | 184,530 |
| Henderson Jane | CFO & SVP, Corp. Dev. | 03/19/2018 | 22,743 |
| Henderson Jane | CFO & SVP, Corp. Dev. | 03/19/2018 | 41,344 |
| Henderson Jane | CFO & SVP, Corp. Dev. | 03/16/2018 | 341,464 |
| Ravina Bernard | Chief Medical Officer | 03/12/2018 | 61,667 |
| Sah Dinah Ph.D. | Chief Scientific Officer | 02/27/2018 | 155,845 |
| Sah Dinah Ph.D. | Chief Scientific Officer | 02/27/2018 | 468,690 |
| Ravina Bernard | Chief Medical Officer | 02/12/2018 | 44,706 |
| Ravina Bernard | Chief Medical Officer | 01/10/2018 | 59,532 |
| Ravina Bernard | Chief Medical Officer | 12/11/2017 | 74,829 |
| Ravina Bernard | Chief Medical Officer | 11/10/2017 | 72,797 |
| Ravina Bernard | Chief Medical Officer | 10/10/2017 | 223,223 |
| Ravina Bernard | Chief Medical Officer | 09/11/2017 | 157,014 |
| Ravina Bernard | Chief Medical Officer | 07/20/2017 | 54,900 |
| Ravina Bernard | Chief Medical Officer | 09/05/2017 | 54,900 |
| PAUL STEVEN M | President and CEO | 01/14/2016 | 140,690 |
| Sanofi | Former 10% owner | 11/16/2015 | 1,750,000 |
Load More Insider Transactions
FUNDS WITH A POSITION IN VOYAGER THERAPEUTICS, INC.
| Fund | # Shares Owned | % of Portfolio | % Change | Investing Style |
|---|---|---|---|---|
| BlackRock Inc. | 5,459,941 | 0.00113% | 2.77% | Other |
| FARALLON CAPITAL MANAGEMENT LLC | 2,292,000 | 0.09% | No change | Event Driven, Value |
| GEODE CAPITAL MANAGEMENT, LLC | 1,072,769 | 0.00074% | 10.33% | Other |
| AQR CAPITAL MANAGEMENT LLC | 502,375 | 0.00609% | -36.7% | Other |
| D. E. SHAW & CO., INC. | 205,601 | 0.00152% | -12.13% | Other |
| RENAISSANCE TECHNOLOGIES LLC | 63,200 | 0.00085% | -50.66% | Other |
| BLACKSTONE INC. | 50,848 | 0.00191% | Exited | Other |
| ALPS ADVISORS INC | 38,149 | 0.00207% | -0.53% | Other |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 32,005 | 0.00518% | Exited | Other |
| BALYASNY ASSET MANAGEMENT L.P. | 21,341 | 0.00035% | Exited | Event Driven |
CHANGE IN SHARES OUTSTANDING FOR VOYAGER THERAPEUTICS, INC.
STOCK BUYBACKS FOR VOYAGER THERAPEUTICS, INC.
Period of Report
Previous Period
% Change in Shares
10-K/10-Q Filings
Quarter
Load More
Period of Report: 03/31/2024
10-K/10-Q Filings: View
Previous Period
% Change in Shares
Quarter
12/31/2023
13.23%
1Q
06/30/2023
31.24%
3Q
03/31/2023
35.47%
4Q
12/31/2022
48.16%
5Q
09/30/2022
44.34%
6Q
06/30/2022
49.14%
7Q
03/31/2022
50.11%
8Q
12/31/2021
51.08%
9Q
09/30/2021
51.18%
10Q
06/30/2021
51.98%
11Q
03/31/2021
52.31%
12Q
12/31/2020
54.82%
13Q
09/30/2020
51.62%
14Q
06/30/2020
54.25%
15Q
03/31/2020
54.52%
16Q
Load More
BUYBACK ANNOUNCEMENT(S) FOR VOYAGER THERAPEUTICS, INC.
LOADING...